BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26953659)

  • 1. Prognostic Role of Early and End-of-Neoadjuvant Treatment 18F-FDG PET/CT in Patients With Breast Cancer.
    García Vicente AM; Amo-Salas M; Relea Calatayud F; Muñoz Sánchez Mdel M; Pena Pardo FJ; Jiménez Londoño GA; Álvarez Cabellos R; Espinosa Aunión R; Soriano Castrejón Á
    Clin Nucl Med; 2016 Jul; 41(7):e313-22. PubMed ID: 26953659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral heterogeneity in
    Molina-García D; García-Vicente AM; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Tello-Galán MJ; Soriano-Castrejón Á; Pérez-García VM
    Ann Nucl Med; 2018 Jul; 32(6):379-388. PubMed ID: 29869770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and delayed prediction of axillary lymph node neoadjuvant response by (18)F-FDG PET/CT in patients with locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón Á; León Martín A; Relea Calatayud F; Muñoz Sánchez Mdel M; Cruz Mora MÁ; Jiménez Londoño GA; Espinosa Aunión R
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1309-18. PubMed ID: 24744045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
    Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predictor: A molecular phenotype approach.
    Garcia Vicente AM; Soriano Castrejón A; Amo-Salas M; Lopez Fidalgo JF; Muñoz Sanchez MM; Alvarez Cabellos R; Espinosa Aunion R; Muñoz Madero V
    Rev Esp Med Nucl Imagen Mol; 2016; 35(3):152-8. PubMed ID: 26522003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
    Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
    Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
    Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
    Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M
    J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
    Palmerini E; Colangeli M; Nanni C; Fanti S; Marchesi E; Paioli A; Picci P; Cambioli S; Donati D; Cevolani L; De Paolis M; Gambarotti M; Ferrari S
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):215-223. PubMed ID: 27645694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
    Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
    Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
    Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.